LLY

918.27

+0.08%↑

JNJ

237.45

-0.46%↓

ABBV

207.44

-1.91%↓

NVS

148.57

-1.68%↓

AZN

188.19

-0.59%↓

LLY

918.27

+0.08%↑

JNJ

237.45

-0.46%↓

ABBV

207.44

-1.91%↓

NVS

148.57

-1.68%↓

AZN

188.19

-0.59%↓

LLY

918.27

+0.08%↑

JNJ

237.45

-0.46%↓

ABBV

207.44

-1.91%↓

NVS

148.57

-1.68%↓

AZN

188.19

-0.59%↓

LLY

918.27

+0.08%↑

JNJ

237.45

-0.46%↓

ABBV

207.44

-1.91%↓

NVS

148.57

-1.68%↓

AZN

188.19

-0.59%↓

LLY

918.27

+0.08%↑

JNJ

237.45

-0.46%↓

ABBV

207.44

-1.91%↓

NVS

148.57

-1.68%↓

AZN

188.19

-0.59%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Avatud

SektorTervishoid

0.46 6.98

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.4

Max

0.46

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+685.11% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-441M 106M
Eelmine avamishind	-6.52
Eelmine sulgemishind	0.46

Uudiste sentiment

By Acuity

57%

43%

298 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. märts 2026, 22:51 UTC

Tulu

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18. märts 2026, 21:40 UTC

Omandamised, ülevõtmised, äriostud

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18. märts 2026, 20:31 UTC

Tulu

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18. märts 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18. märts 2026, 23:31 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

18. märts 2026, 22:49 UTC

Market Talk

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18. märts 2026, 22:41 UTC

Market Talk

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18. märts 2026, 22:36 UTC

Tulu

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18. märts 2026, 22:24 UTC

Tulu

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18. märts 2026, 22:23 UTC

Tulu

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18. märts 2026, 22:23 UTC

Tulu

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18. märts 2026, 21:58 UTC

Tulu

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18. märts 2026, 21:55 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

18. märts 2026, 21:55 UTC

Market Talk

Tulu

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18. märts 2026, 21:40 UTC

Market Talk

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18. märts 2026, 21:16 UTC

Market Talk

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18. märts 2026, 21:00 UTC

Uudisväärsed sündmused

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18. märts 2026, 20:58 UTC

Tulu

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18. märts 2026, 20:41 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:29 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:25 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:17 UTC

Tulu

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18. märts 2026, 20:14 UTC

Market Talk

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18. märts 2026, 20:09 UTC

Tulu

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18. märts 2026, 20:07 UTC

Tulu

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18. märts 2026, 20:06 UTC

Tulu

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology Sees 3Q Gross Margin About 81% >MU

18. märts 2026, 20:03 UTC

Tulu

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

685.11% tõus

12 kuu keskmine prognoos

Keskmine 3.69 USD 685.11%

Kõrge 15 USD

Madal 0.3 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

298 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.